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Polyglutamine(polyQ)-expanded proteins are poten-
tial therapeutic targets for the treatment of polyQ
expansion disorders such as Huntington’s disease
(HD) and spinocerebellar ataxia type 3 (SCA3). Here,
we used an amino-terminal fragment of a mutant
Huntingtin protein (Htt-N-82Q) as bait in an unbiased
screen of a 60,000 peptoid library. Peptoid HQP09
was selected from the isolated hits and confirmed
as a specific ligand of Htt-N-82Q and Atxn3-77Q
mutant proteins in biochemical experiments. We
identified three critical residues in the HQP09
sequence that are important for its activity andgener-
ated aminimal derivative, HQP09_9, whichmaintains
the specificpolyQ-binding activity.Wedemonstrated
that HQP09 and HQP09_9 inhibited aggregation of
Htt-N-53Q in vitro and exerted Ca2+-stabilizing and
neuroprotective effects in experiments with primary
striatal neuronal cultures derived from HD mice. We
further demonstrated that intracerebroventricular
delivery of HQP09 to an HD mouse model resulted
in reduced accumulation of mutant Huntingtin aggre-
gates and improved motor behavioral outcomes.
These results suggest that HQP09 and similar pep-
toids hold promise as novel therapeutics for devel-
oping treatments for HD, SCA3, and other polyglut-
amine expansion disorders.
INTRODUCTION
The abnormal expansion of polyglutamine (polyQ) tracks in
the coding sequences of several proteins causes misfolding
of these proteins and initiates neurodegenerative diseases
including Huntington’s disease (HD), spinocerebellar ataxia type
3 (SCA3), and several other related disorders (Gusella and Mac-
Donald, 2000; The Huntington’s Disease Collaborative Research
Group, 1993). Polyglutamine expansions longer than 35Q in theChemistry & Biology 18, 1113–112context of Huntingtin (Htt) or ataxin-3 (Atxn3) proteins result in
HD and SCA3, respectively. The neuropathological hallmark of
HD is the selective degeneration of medium spiny neurons
(MSNs) in the striatum (caudate nucleus and putamen) (Vonsattel
and DiFiglia, 1998; Vonsattel et al., 1985). The brain regions most
affected in SCA3 are the dentate and pontine nuclei, internal
portion of globus pallidus, subthalamic nucleus, substantia nigra
(SN), and spinocerebellar tracts (Stevanin et al., 2000). Polyglut-
amine-expanded proteins are prone to form aggregates and
nuclear inclusions, which may be toxic to neurons (Shao and Dia-
mond, 2007). However, the exact mechanism(s) responsible for
such toxicity are unknown. These proteins are involved in a num-
ber of pathological interactions with signaling proteins in cells,
causing abnormalities in transcription, proteosomal and mito-
chondrial functions, Ca2+ signaling, and other essential cellular
functions. One potential therapeutic approach is to target these
downstream signaling pathways and to correct signaling abnor-
malities induced by the expression of polyQ-expanded proteins.
Such an approach has been extensively discussed for trans-
criptional, mitochondrial, and Ca2+ signaling pathways (Benn
et al., 2008; Bezprozvanny, 2009; Chaturvedi and Beal, 2008).
An alternative strategy is to target themutant polyQ-expanded
mutant protein itself and prevent the detrimental downstream
signaling altogether. The silencing of mutant Htt (mHtt) by
RNAi-encoding viruses resulted in the improved behavioral
and neuropathological abnormalities in a mouse model of HD
(Harper et al., 2005). Likewise, viral delivery of short hairpin
RNAs specific for mutant ataxin-1 (mAtxn1) resolved character-
istic Purkinje cell inclusions, restored cellular morphology, and
profoundly improved motor coordination in SCA type 1 mice
(Xia et al., 2004). Recently, the selective knockdown of mRNA
encoding mHtt and mAtxn3 proteins has been demonstrated
using peptide nucleic acid (PNA) and locked nucleic acid (LNA)
antisense oligomers targeting expanded CAG repeat (Hu et al.,
2009). These antisense oligomers effectively silence the mutant
mRNA while leaving wild-type (WT) Htt and Atxn3 mRNA levels
intact (Hu et al., 2009).
Another potential therapeutic strategy would be to target the
mutant proteins directly by inhibiting their ability to form toxic
aggregates. Proteins containing polyQ expansions can exist
in multiple conformations, some of which are innocuous and
some of which are aggregation-prone and toxic (Shao and5, September 23, 2011 ª2011 Elsevier Ltd All rights reserved 1113
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Peptoids as HD TherapeuticsDiamond, 2007). For example, it has been shown that an increase
in chaperone levels can shift the balance away from toxic confor-
mations of polyQ-expandedproteins and reduce toxicity (Wacker
et al., 2004; Warrick et al., 1999; Wyttenbach et al., 2002). Intra-
bodies developed against an epitope of human Htt reduced
the specific neurotoxicity of mHtt by preventing its accumulation
in neuronal processes and promoting its clearance from the
cytoplasm (Colby et al., 2004; Khoshnan et al., 2002; Lecerf
et al., 2001;Wolfgang et al., 2005). Furthermore, a specific polyQ
binding peptide (QBP1), identified from a combinatorial peptide
library expressed on M13 phage pIII protein (Nagai et al., 2000),
has been reported to prevent the toxic conformational transition
within polyQ-expanded proteins (Nagai et al., 2000) and exert
neuroprotective effects in cellular and fly models of polyQ
toxicity (Nagai et al., 2003;Popiel et al., 2007, 2009). Several small
molecules have been isolated in screens as inhibitors of polyQ
aggregation and some were able to reduce polyQ aggregation
and toxicity in cellular and animal models (Chopra et al., 2007;
Ehrnhoefer et al., 2006; Heiser et al., 2002; Sa´nchez et al., 2003;
Wang et al., 2005; Zhang et al., 2005). However, none of these
small-molecule candidates have successfully advanced into clin-
ical trials because of problems in finding an appropriate mode of
delivery, poor pharmacokinetics, and low efficacy in vivo.
The goal of the present study was to identify a polyQ-binding
small molecule with ‘‘drug-like’’ properties that would have the
potential to inhibit the formation of toxic protein aggregates.
The approach was to take advantage of an efficient peptoid
library synthesis and screening technology. Peptoids (oligomers
of N-substituted glycines) were developed as scaffolds for the
generation of chemically diverse libraries of novel molecules
(Simon et al., 1992) and they have been proven to be a rich
source of specific ligands for many types of proteins, including
several that have never before been targeted pharmacologically
(Zuckermann and Kodadek, 2009). In the present study a one-
bead-one-compound peptoid library was synthesized, con-
taining 60,000 unique compounds. The generated library was
screened for molecules that specifically bound an amino-
terminal fragment of the mHtt protein (Htt-N-82Q) fused to
maltose-binding protein (MBP). A peptoid called HQP09 was
isolated in the screen and confirmed as a specific mHtt and
mAtxn3 binding partner in biochemical experiments. A minimal
derivative peptoid HQP09–9 was produced as a result of the
structure-activity relationship analysis of HQP09. The actions
of HQP09 and HQP09–9 were characterized in an in vitro aggre-
gation assay with mHtt and in cellular toxicity assays with pri-
mary MSN cultures prepared from YAC128 mice. Furthermore,
delivery of HQP09 by intracerebroventricular (ICV) injection
decreases mHtt aggregation in YAC128 mice. These results
argue that, in general, direct pharmacological blockade of polyQ
aggregation is possible and that peptoids in particular hold
promise as lead compounds for the development of drugs
against HD, SCA3, and other polyQ-expansion disorders.
RESULTS
The Identification of Peptoid HQP09 from a Library
as a Ligand for mHtt
To identify a mHtt-binding peptoid, we generated a bead-
displayed peptoid library composed of 60,000 diverse 6-mer1114 Chemistry & Biology 18, 1113–1125, September 23, 2011 ª201peptoids on TentaGel macrobeads (see Methods for details). In
the general structure of the library (Figure 1A), a proline was fixed
at the fourth position, whereas the other five positions were
randomized using nine different primary amines (Figure 1B).
The fixed proline residue was selected because proline has
been reported to be essential for the association of the QBP1
peptide with polyQ-expanded proteins (Hamuro et al., 2007). A
residue containing a hydroxyethyl side group was added
between the 6-mer peptoid and the resin to provide a consistent
residue to aid in mass spectrometry–based characterization
and to increase solubility. Mutant Htt proteins that harbor more
than 35 glutamine residues easily aggregate in vitro, but for
screening purposes soluble mHtt is required. To address this
issue, we generated a fusion protein between Htt-82Q amino-
terminal and a MBP (MBP-Htt-N-82Q). For comparison, WT
MBP-Htt-N-15Q protein was also expressed and purified.
BothMBP-Htt-N-82Q andMBP-Htt-N-15Q proteins weremono-
meric and stable in solution (data not shown).
The MBP-Htt-N-82Q protein was used as bait to screen the
60,000 peptoid library using a recently developed beads-based
screening method (Xiao et al., 2007). The beads were initially
incubated with MBP-Htt-N-82Q protein and then beads with
bound protein were visualized using anti-MBP mouse mono-
clonal antibodies and goat anti-mouse antibodies-coated red
quantum dots (Qdots) (see Methods for details). The beads dis-
playing potential hits were identified by the red halo (Qdot posi-
tive) visible on the bead surface under a fluorescence micro-
scope at excitation wavelength of 410 nm (Figure 1C). Twenty
such beads were picked using a micropipette. To eliminate
beads that might bind the antibodies rather than the target
protein, all proteins were stripped off the beads using SDS and
probed again with biotinylated MBP-Htt-N-82Q protein and
streptavidin-coated Qdots. Ten of the 20 beads were positive
in the re-screening assay with biotinylated MBP-Htt-N-82Q
protein, suggesting that they recognize MBP-Htt-N-82Q protein
directly. The peptoids on these 10 beads were sequenced by
Edman degradation and designated as HQPs (Huntingtin poly-
Q binding Peptoids). Because some of these peptoids had
similar sequences (see Figure S1 available online), only five
representative peptoids—HQP02, HQP04, HQP06, HQP07,
and HQP09—were re-synthesized on TentaGel beads and
evaluated in the Qdot binding experiments with MBP-Htt-N-
82Q protein. No binding was detected for HQP02, HQP04,
HQP06, or HQP07 beads. However, strong binding was de-
tected for HQP09 beads (data not shown). The HQP09 beads
also displayed significantly stronger binding to MBP-Htt-N-
82Q than to MBP-Htt-N-15Q (data not shown). Thus, we
selected HQP09 (Figure 2A) as a specific mHtt ligand for further
evaluation.
HQP09 Specifically Binds to polyQ-Expanded Proteins
In Vitro
In the next series of experiments, we evaluated the association
between the peptoid HQP09 and mHtt using conventional bio-
chemical binding assays. TentaGel beads displaying HQP09
were incubated with recombinant MBP-Htt-N-82Q or MBP-
Htt-N-15Q proteins and precipitated by centrifugation. Attached
proteins were resolved by gel electrophoresis and analyzed
by western blotting with anti-MBP monoclonal antibodies. The1 Elsevier Ltd All rights reserved
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Figure 1. Peptoid Library Used in the Screen for Specific mHtt Ligands
(A) General chemical structure of the 6-mer peptoid library containing a fixed proline residue at the 4th position and 5 variable positions (R1-R5). The calculated
diversity of the library is 59,049 diverse peptoids.
(B) Chemical structures and names of 9 amines used in synthesizing the peptoid library.
(C) A fluorescence microscopic image showing a representative hit isolated from the peptoid library as a potential ligand for MBP-Htt-N-82Q protein. The bead
containing a putative hit (shown by the red arrow) is identified by a red halo around the bead resulting from Qdot fluorescence. Scale bar represents 170 mm.
See also Figure S1.
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Peptoids as HD TherapeuticsTentaGel beads containing a random 6-mer peptoid RP01 (Fig-
ure 2A) were used as a negative control, whereas streptavidin-
coated beads conjugated with biotinylated Bio-(QBP1)2 tandem
peptide (Nagai et al., 2000) were used as a positive control.
Consistent with previous observations (Nagai et al., 2000), Bio-
(QBP1)2 beads retained about 50% of the input MBP-Htt-N-
82Q but only a trace amount of MBP-Htt-N-15Q (Figure 2B).
The HQP09 beads retained about 40% of the input MBP-Htt-
N-82Q but none of the MBP-Htt-N-15Q (Figure 2B). Control
RP01 beads did not associate with either protein (Figure 2B).
These data suggested that HQP09 specifically bound expanded
mHtt protein and that HQP09 peptoid and Bio-(QBP1)2 peptide
bound mHtt with similar affinities.
Is HQP09 specific for mHtt or does it bind to other polyQ-
expanded proteins as well? To answer this question, we per-
formed pull-down experiments using HQP09 beads incubated
with full length WT Atxn3-19Q and mutant Atxn3-77Q. The
precipitated proteins were detected by western blotting with
an anti-Atxn3 monoclonal antibody. The data show that
HQP09 beads bind to Atxn3-77Q protein more efficiently than
to Atxn3-19Q protein (Figure 2C). The control beads coated
with the RP01 peptoid did not bind either protein (Figure 2C).
The beads attached to Bio-(QBP1)2 peptide precipitated
similar amounts of Atxn3-77Q and Atxn3-19Q proteins (Fig-
ure 2C). From these results we concluded that HQP09 peptoid
bound to multiple polyQ-expanded proteins and that the
specificity of HQP09 for an expanded polyQ track was com-
parable with, or better than, the specificity of the Bio-(QBP1)2
peptide.Chemistry & Biology 18, 1113–112To obtain greater insight into the binding of HQP09 tomHtt, we
performed a series of competitive binding experiments. In these
experiments, QBP1 peptide (at 100 mM or 300 mM), HQP09 pep-
toid (300 mM), or control RP01 peptoid (300 mM) were included
in the binding reaction between HQP09-displaying beads and
MBP-Htt-N-82Q protein. The peptoid-bound proteins were ana-
lyzed by western blotting with anti-MBP monoclonal antibodies.
We found that the addition of soluble HQP09 peptoid reduced
the fraction of precipitated MBP-Htt-N-82Q protein, but the
addition of control RP01 peptoid or QBP1 peptide had no effect
(Figure 2D). In reverse experiments, we determined that QBP1
peptide, but not HQP09 or RP01 peptoids, reduced the fraction
of MBP-Htt-N-82Q protein bound by QBP1 peptide-displaying
beads (Figure 2E). Taken together (Figure 2D, 2E), these results
suggest that HQP09 and QBP1 do not compete with each other,
but rather bind to non-overlapping sites on the MBP-Htt-N-82Q
protein. Consistent with previous observations (Figures 2B and
2C), we confirmed that HQP09 was selective for mutant MBP-
Htt-N-82Q protein (Figure 2D), whereas QBP1-displaying beads
associated with the WT MBP-Htt-N-15Q protein to a significant
degree (Figure 2E).
Structure-Activity Analysis of HQP09
To determine the affinity of the HQP09 association with mHtt
in solution, we developed a solution phase fluorescence po-
larization (FP) assay between fluorescein-labeled HQP09
(HQP09_G2_Fluo) (Figure 3A) and MBP-Htt-N-82Q. The associ-
ation of HQP09_G2_Fluo with the target protein leads to a reduc-
tion in the rotational mobility of the fluorescein label, which could5, September 23, 2011 ª2011 Elsevier Ltd All rights reserved 1115
Figure 2. HQP09 Peptoid Specifically Binds to polyQ-Expanded Proteins
(A) Chemical structure of HQP09 peptoid identified from the screen of the peptoid library. RP01 is a random 6-mer peptoid used as a negative control.
(B) MBP-Htt-N-82Q or MBP-Htt-N-15Q recombinant proteins were used in pull-down experiments with bio-(QBP1)2, HQP09 or RP01 beads. The precipitated
fractions were analyzed by western blotting with anti-MBP monoclonal antibodies.
(C) Atxn3-77Q or Atxn3-19Q recombinant proteinswere used in pull-down experimentswith bio-(QBP1)2, HQP09, or RP01 beads. The precipitated fractions were
analyzed by western blotting with anti-Atxn3 monoclonal antibodies.
(D and E) MBP-Htt-N-82Q and MBP-Htt-N-15Q recombinant proteins were used in pull-down experiments with HQP09 beads (D) or QBP1 beads (E). The QBP1
peptide, HQP09 peptoid, or RP01 peptoid were added in binding reaction as indicated. The precipitated fractions were analyzed by western blotting with an
anti-MBP monoclonal antibody.
On (A–E), the input lane contained 1% of total protein used in pull-down experiments.
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Peptoids as HD Therapeuticsbe quantified as an increase in FP values (Dmp). In our
experiments, 5 nM of HQP09_G2_Fluo was incubated with
increasing concentrations of MBP-Htt-N-82Q in the presence
of 1.0 mM bovine serum albumin (BSA). The results were consis-
tent with a Kd value of 12 mM for the association between
HQP09_G2_Fluo and MBP-Htt-N-82Q (Figure 3B). A control
titration experiment using HQP09_G2_Fluo and BSA alone
showed no apparent association (Figure 3B). The FP-quantified
binding of HQP09_G2_Fluo to MBP-Htt-N-82Q was out-
competed in the presence of 300 mM of the parental peptoid
HQP09 but not in the presence of 300 mM of the control peptoid
RP01 (Figure 3C). These data confirmed that HQP09 specifically
bound to MBP-Htt-N-82Q in solution.
In the next series of experiments, we took advantage of
FP-based binding assays to identify the structural determinants
responsible for association of HQP09 with mHtt. Our first aim1116 Chemistry & Biology 18, 1113–1125, September 23, 2011 ª201was to define the minimum pharmacophore responsible for the
HQP09 binding activity. For that purpose, we used sarcosine
scanning, a method that we have recently applied successfully
to identifying the minimum pharmacophore of a peptoid
antagonist of VEGFR2 (Udugamasooriya et al., 2008b). A series
of sarcosine scanning derivatives was obtained by replacing
one of the seven residues in HQP09 (Figure 3A, positions 1–7)
with a sarcosine. The corresponding seven peptoids (HQP09_1
to HQP09_7, Figure S2) were synthesized and used at a con-
centration of 300 mM in competitive FP binding assays with
HQP09_G2_Fluo and MBP-Htt-N-82Q. We found that
HQP09_1 and HQP09_2 had no effect on FP signal and that
HQP09_4 reduced FP signal by 50% (Figure 3C). HQP09_3,
HQP09_5, HQP09_6, and HQP09_7 were as potent as HQP09 it-
self and reduced FP signal by more than 75% (Figure 3C). These
data suggested that three of the seven residues of HQP09—11 Elsevier Ltd All rights reserved
Figure 3. Structure-Activity Studies of HQP09 using Fluorescence Polarization mHtt-Binding Assay
(A) Chemical structures of HQP09_G2 and HQP09_G2_Fluo.
(B) Fluorescence polarization assay. 5 nM of HQP09_G2_Fluo was incubated with indicated amounts of BSA or MBP-Htt-N-82Q protein in 1 mM BSA. The
fluorescence polarization values (Dmp) are shown at each protein concentration as mean ± SE (n = 3) for BSA (filled squares) or MBP-Htt-N-82Q (open circles).
The fit to the titration curve (smooth line) yielded apparent kdz12 mM for MBP-Htt-N-82Q association with HQP09.
(C) Competitive fluorescence polarization assay. HQP09 peptoid, RP01 peptoid or the seven sarcosine scan derivatives of HQP09 as indicated were added in
a final concentration of 300 mM to a binding assay between 5 nM HQP09_G2_Fluo and 5 mM MBP-Htt-N-82Q. The fluorescence polarization values (Dmp)
measured in the absence (con) or presence of each peptoid are shown asmean ± SE (n = 3). The significant reduction inDmp values when compared with control
is shown (***p < 0.001, **p < 0.01).
(D) Chemical structures of four 4-mer HQP09 analogs.
(E) Results of competitive fluorescence polarization assay performed with HQP09, 4-mer HQP09 analogs, and RP01 (300 mMeach). The assay was performed as
described in (C) and Dmp values presented asmean ± SE (n = 3). HQP09 and HQP09_9 significantly reduced measured Dmp values when compared with control
(***p < 0.001, *p < 0.05). Other 4-mer analogs had no significant effect (p > 0.05).
See also Figure S2 and Table S1.
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Peptoids as HD Therapeutics(Npip), 2 (Nmba), and 4 (Nmea) (Figures 1B and 3A)—constituted
a minimal pharmacophore important for the association of the
peptoid with MBP-Htt-N-82Q, where positions 1 (Npip) and 2
(Nmba) play a predominant role.
With this information, we aimed at generating a minimally ac-
tive derivative of HQP09. We reasoned that a smaller molecule
would be more advantageous for biological assays and have
better potential as a lead for drug development. To achieve this
goal, we synthesized four peptoid derivatives of HQP09 named
HQP09_8, HQP09_9, HQP09_10, and HQP09_11 (Figure 3D).
The activities of these peptoid derivatives were tested at 300 mM
in competitive FP assays with HQP09_G2_Fluo and MBP-Htt-N-
82Q. We found that HQP09_9 inhibited FP signal by more than
50%, HQP09_8 was modestly effective, and HQP09_10 and
HQP09_11 were ineffective (Figure 3E). Although HQP09_9 was
less effective than HQP09 (Figure 3E), the molecular weight of
HQP09_9 (MW = 585) was 1.6-fold lower than the molecularChemistry & Biology 18, 1113–112weight of HQP09 (MW = 908). Thus, we selected HQP09_9 as
the lead HQP09 derivative for cell-based assay evaluation.
PolyQ-Binding Peptoids Inhibit mHtt Aggregation
In Vitro
Polyglutamine-expanded proteins are prone to aggregation, and
aggregation of mHtt may contribute to its toxicity (Shao and
Diamond, 2007). We aimed to evaluate the anti-aggregation
activities of HQP09 and HQP09_9 peptoids using an in vitro
aggregation assay of mHtt as previously described (Wacker
et al., 2004). The random peptoid RP01 and inactive analog
HQP09_01 (Figure S2) were used as controls to verify the speci-
ficity of the observed effects, and the polyQ-binding peptide
QBP1 (Nagai et al., 2000) was used as a positive control for
anti-aggregation activities. The first exon of Htt-53Q protein
was expressed in bacteria as a glutathione S-transferase (GST)
fusion protein and purified as previously described (Wacker5, September 23, 2011 ª2011 Elsevier Ltd All rights reserved 1117
Figure 4. PolyQ-Binding Peptoids Inhibit mHtt Aggregation
(A) Filter trap assay. The Htt53Q aggregates formed after 24 hr incubation
were trapped and detected by MW8 antibodies. The aggregation reaction was
performed in the presence of 3% DMSO, QBP1 peptide, HQP09, HQP09_9,
HQP09_1, or RP01 peptoids (10 mM each) as indicated. The amounts of
Htt53Q aggregates were quantified by using densitometry of MW8 signals and
normalized to the signal observed in DMSO control in the same experiment.
The averaged and normalized results are presented as mean ± SE (n = 3
independent experiments).
(B) AFM images of Htt53Q aggregates formed after 24 hr incubation in the
presence of 3%DMSO, QBP1 peptide, HQP09, HQP09_9, HQP09_1, or RP01
peptoids (10 mM each) as indicated. The particles corresponding to fibrils and
oligomers formed by Htt53Q are clearly visible in DMSO control (top left) and
in the presence of HQP09_1 (bottom center) or RP01 (bottom right). The
number of particles is reduced in the presence of QBP1 (top center), HQP09
(top right), and HQP09_9 (bottom left).
Scale bar represents 2 mm for all panels. Quantification of the number of
particles over 100 nm detected on these images is shown as Figure S3B.
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Peptoids as HD Therapeuticset al., 2004). After purification, GST-Htt53Q appeared non-
aggregated by the atomic force microscopy (AFM) analysis and
by size-exclusion chromatography (data not shown). Cleavage
of a unique peptide sequence between the GST moiety
and Htt53Q with a site-specific protease releases the Htt53Q
fragment, initiating aggregation in a time-dependent manner
(Wacker et al., 2004). To measure the degree of Htt53Q aggre-
gation we used a filter trap assay in which detergent-insoluble
mHtt aggregates were detected by the anti-Htt MW8 antibody
(Wacker et al., 2004). Large amounts of trapped Htt53Q aggre-
gates were detected in samples collected 24 hr after cleavage
from GST (Figure 4A). The addition of 10 mM QBP1 peptide
inhibited Htt53Q aggregation by 40% (Figure 4A), consistent
with published results (Nagai et al., 2007). When tested with the
same concentration (10 mM), HQP09 peptoid inhibited Htt53Q
aggregation by 80%, significantly better than QBP1 peptide
(Figure 4A). The HQP09_9 derivative inhibited Htt53Q aggrega-
tion by 30%, not significantly different from the QBP1 peptide
(Figure 4A). The control peptoids RP01 and HQP09_1 were not
effective inpreventingHtt53Qaggregation (Figure 4A). In addition
to the filter trap assay, the formation of Htt53Q aggregates was
also evaluated by SDS-PAGE gel followed by western blotting
with MW8 antibody. When analyzed by SDS-PAGE assay per-
formed after 24 hr incubation, we found that the HQP09 peptoid
and QBP1 peptide effectively reduced the formation of mHtt
aggregates, HQP09_9 peptoid was partially effective, and
RP01 and HQP09_1 peptoids had no effect (Figure S3A).
To further characterize the inhibition of Htt53Q aggregation by
HQP09 and HQP09_09, we used atomic forcemicroscopy (AFM)
to image the structures of aggregates (oligomers or fibrils) in
solution. Before AFM imaging, samples of Htt53Q solution taken
after the 24 hr incubation were diluted 20 times so as to clearly
image individual fibrils or oligomers on the surface. Large fibrils
and oligomers were observed in control AFM experiments
when Htt53Q was incubated with 3%DMSO (Figure 4B). Forma-
tion of the AFM-visible fibrils and oligomers was abolished in the
presence of QBP1 peptide, HQP09 peptoid, or HQP09_9 pep-
toid (Figure 4B). In contrast, a large number of fibrils and oligo-
mers were observed in the presence of RP01 or HQP09_1 pep-
toids (Figure 4B). Quantification of the number of observed
particles larger than 100 nm, as analyzed by AFM, is shown on
Figure S3B. Overall, results from the filter trap assay, SDS-
PAGE, and AFM imaging experiments indicated that HQP09
and HQP09_9 peptoids were highly effective in inhibiting mHtt
aggregation. The abilities of HQP09 and HQP09_9 to inhibit
mHtt aggregation were comparable with the activity of the
previously identified QBP1 peptide (Nagai et al., 2000) and the
anti-aggregation effects of the peptoids were specific, because
random peptoid RP01 and the inactive derivative HQP09_01
had no such effect in any of these aggregation assays.
PolyQ-Binding Peptoids Stabilize Glutamate-Induced
Ca2+ Signaling in YAC128 MSN
Mutant Htt binds to a number of Ca2+ channels and signaling
proteins, and deranged neuronal Ca2+ signaling plays an im-
portant role in HD pathogenesis (Bezprozvanny, 2009). In our
previous studies, we found that repetitive pulses of 20 mM gluta-
mate resulted in a larger elevation of cytosolic Ca2+ levels in
YAC128 MSN when compared with WT MSN (Tang et al.,1118 Chemistry & Biology 18, 1113–1125, September 23, 2011 ª2012005). Could HQP09 or HQP09_9 peptoids sequester mHtt
and stabilize abnormal Ca2+ signals in HD MSN? To evaluate
the biological activity of HQP09 or HQP09_9 peptoids, we per-
formed Ca2+ imaging experiments with MSN cultures derived
from WT and YAC128 mice preincubated with 20 mM HQP09
or HQP09_9 peptoids. Random peptoid RP01 was used in the
same concentration (20 mM) as a control for the specificity of
the observed effects. The peptoids were added to the culture
media at day in vitro (DIV)1 and DIV13 to allow sufficient time
for bindingmHtt, and Ca2+ imaging experiments were performed
at DIV13 as previously described (Tang et al., 2005). The1 Elsevier Ltd All rights reserved
Figure 5. PolyQ-Binding Peptoids Stabilize Gluta-
mate-Induced Ca2+ Signals in HD-YAC128 MSN
(A) Repetitive application of 20 mM glutamate (shown as
black bars) induces enhanced Ca2+ signals in MSN
cultures from HD-YAC128 mice. The intracellular Ca2+
concentration is measured by Fura-2 ratio imaging and
presented as 340/380 Fura-2 ratio at each time point in the
experiment.
(B–D) The same experiment as in panel (A) was performed
after preincubation with 20 mM HQP9 (B), HQP9_9 (C), or
RP01 (D). On (A–D), the representative trace from all HD-
YAC128 MSN in each experimental group are shown.
(E) The summary of Ca2+ increase in WT (open column)
and YAC128 (filled column) MSN after 20 pulses of
glutamate. The average increase in Ca2+ levels is shown
by change in 340/380 ratio as mean ± SE (nR 33 for the
number of MSN analyzed in each group). Preincubation
with HQP09 or HQP09_9 significantly (***p < 0.001)
attenuated glutamate-induced Ca2+ responses in YAC128
MSN. HQP09_9 peptoid had significantly (*p < 0.05)
stronger effect thanHQP09. RP01 had no significant effect
(ns) on YAC128 MSN Ca2+ signals.
Chemistry & Biology
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was continuously monitored by Fura-2 imaging and the 340/
380 ratio was used to quantify Ca2+ levels. In agreement with
our previous findings (Tang et al., 2005, 2007), the increase in
Ca2+ levels after 20 pulses of 20 mM glutamate was significantly
higher in YAC128MSN than in WTMSN (Figures 5A and 5E). The
glutamate-induced Ca2+ increase in YAC128 MSN cultures was
significantly reduced by the addition of HQP09 or HQP09_9 pep-
toids (Figures 5B, 5C, and 5E). In contrast, RP01 had no effect on
glutamate-induced Ca2+ signals in YAC128 MSN (Figure 5D, E).
The effects of HQP09 and HQP09_9 were specific for YAC128
MSN and the addition of these peptoids did not have any signif-
icant effect on glutamate-induced Ca2+ signals in WT MSN (Fig-
ure 5E) or on basal Ca2+ levels (data not shown). HQP09_9 ap-
peared to be the more effective ‘‘Ca2+ stabilizer’’ compared
with HQP09 (Figure 5E), most likely because of the increased
membrane permeability of the small derivative.
PolyQ-Binding Peptoids Are Neuroprotective in Cellular
HD Model
The polyQ-binding peptoids prevent mHtt aggregation (Fig-
ure 4; Figure S3) and stabilize abnormal Ca2+ signals inChemistry & Biology 18, 1113–1125, September 23,YAC128 MSN (Figure 5). These results sug-
gested that polyQ-binding peptoids could
sequester mHtt and potentially reduce its
toxicity. To evaluate the potential neuroprotec-
tive effects of polyQ-binding peptoids, we took
advantage of the glutamate toxicity assay
with YAC128 MSN cultures that we previously
developed and have used extensively in
testing potential HD neuroprotective agents
(Hu et al., 2009; Tang et al., 2005, 2007,
2009; Wu et al., 2006, 2008, 2009, 2011). As
in the Ca2+ imaging experiments, HQP09,
HQP09_9, or RP01 (20 mM each) were added
to WT and YAC128 MSN cultures on DIV1and DIV13. The apoptotic cell death of cultured MSN neurons
was scored by TUNEL staining as we previously described
(Tang et al., 2005). In basal conditions, approximately 5% of
MSNs were apoptotic (TUNEL-positive) in all experimental
groups (Figure 6B), indicating that peptoids were not toxic
for the cultured neurons at the concentrations tested. Consis-
tent with our previous studies (Tang et al., 2005; Wu et al.,
2011), the addition of 250 mM glutamate for 8 hr increased
the percentage of apoptotic neurons to 60%–70% in YAC128
MSN (Figures 6A and 6B), but only to 30% in WT MSN (Figures
6A and 6B). In the presence of HQP09 and HQP09_9, the
percentage of apoptotic YAC128 neurons was reduced to
30% and 21% respectively, to similar levels as WT neurons
(Figures 6A and 6B). The presence of RP01 had no significant
effect on the glutamate-induced cells death of YAC128 MSN
(Figures 6A and 6B). From these experiments, we concluded
that HQP09 and HQP09_9 exerted significant and specific
neuroprotective effects on the excitotoxic cell death of
YAC128 MSNs. Consistent with Ca2+ imaging studies (Figure 5),
HQP09_9 appeared to be more neuroprotective than HQP09
(Figure 6B), presumably because of its better membrane
permeability.2011 ª2011 Elsevier Ltd All rights reserved 1119
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Figure 6. PolyQ-Binding Peptoids Protect
HD-YAC128 MSN from Glutamate-Induced
Apoptosis
(A) Representative images of TUNEL staining of
MSN cultures from WT (top) and HD-YAC128
(bottom) mice. The MSN cultures were exposed to
250 mM glutamate for 8 hr, fixed, and analyzed by
TUNEL staining (green) with propidium iodide
counterstaining (red). Scale bar represents 40 mm.
The images are shown for control cultures (first
column), and for cultures preincubated with 20 mM
of HQP09 (second column), HQP09_9 (third
column), or RP01 (fourth column).
(B) The fraction of TUNEL-positive nuclei from WT
(black bars) and HD-YAC128 (red bars) MSN
cultures was calculated in the absence of gluta-
mate stimulation and after 250 mM glutamate
stimulation as indicated. The data are presented as
mean ± SE (n = 6 microscopic fields, 200–300
MSNs per field). The fraction of TUNEL-positive
YAC128 MSN nuclei was significantly (**p < 0.01,
***p < 0.001) reduced after preincubation with
HQP09 and HQP09_9. Preincubation with RP01
had no significant effect (n.s.) on apoptosis of
YAC128 MSN.
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in the Brain of YAC128 Mice
PolyQ-binding peptoids prevent the aggregation of mHtt 53Q
proteins in vitro (Figure 4; Figure S3) and were neuroprotective
in a cell toxicity assay using MSN cultures from YAC128 mice
(Figure 6). To determine whether these peptoids had a protective
effect in vivo, we decided to treat WT and YAC128 mice with
peptoids and assess the impact of treatment on mHtt aggrega-
tion and stereotypic YAC128 behavior. In the previous studies,
we used a similar in vivo approach to evaluate efficacy of poten-
tial HD therapeutic agents (Tang et al., 2007, 2009; Wang et al.,
2010). The peptoid derivative HQP09_9 (20 mg/200 ml/mice, in
saline) was delivered subcutaneously to YAC128 and WT mice
using an Alzet osmotic pump for 8 months, beginning at the
age of 3 months and replacing the pump every month. However,
we did not observe a beneficial effect of HQP09_9 on the motor
coordination of YAC128 mice compared with the control group,
nor did we observe a decrease in the staining ofmHtt aggregates
in the striatum (data not shown). Most likely these negative
results were related to poor blood-brain barrier permeability of
HPQ09_9 (data not shown), so that therapeutic concentrations
of HPQ09_9 have not been reached in striatum of YAC128
mice with subcutaneous delivery.
To bypass this problem, in the next series of experiments we
used intracerebroventricular (ICV) infusion of peptoids using
the Alzet osmotic pump (2.5 mg/100 ml/mice, in saline). In these
experiments we also switched our focus to HQP09, which
showed the strongest inhibition effect in the in vitro aggregation
assay (Figure 4). In control experiments, we demonstrated that
after one month of ICV infusion, the concentration of HQP09 in
the brain was 100 times higher than in plasma (Table S2). Our
data also demonstrate that HQP09 accumulated in the brain as
the concentration of HQP09 after 21 days of infusion was signif-1120 Chemistry & Biology 18, 1113–1125, September 23, 2011 ª201icantly higher than it was after only 7 days (Table S2). To evaluate
the therapeutic potential of HQP09, the ICV infusion experiments
were initiated with 8–9-month-old WT and YAC128 mice. The
performance of WT and YAC128 mice on the beam-walk test
was recorded before and after 1 month ICV delivery of HQP09.
In control experiments, WT and YAC128 mice of the same age
were infused with carrier solution alone (ACSF). The ratio (perfor-
mance after treatment/performance before treatment) of the
beam-walk latency in the HQP09-treated group was better
than in the ACSF control group and there was little effect of treat-
ment on the two groups ofWTmice (Figure S4). Importantly, both
the area and intensity of mHtt aggregates significantly reduced
in the striatum region of YAC128 brain after 30-day treatment
with HQP09 when compared with the ACSF control group
(Figures 7A–7C). These data suggest that HQP09 could inhibit
mHtt aggregates in vivo, and the ability of HQP09 to accumulate
in the brain may be one of the therapeutic advantages of pep-
toids in comparison to peptides. In control histological experi-
ments, we confirmed that infusion with HQP09 peptoid did not
result in toxicity to striatal neurons when compared with ACSF
infusion (Figure S5).
DISCUSSION
Polyglutamine-expanded proteins adopt aggregate conforma-
tions that lead to pathological interactions with signaling proteins
in cells (Shao and Diamond, 2007). Thus, specific polyQ-binding
ligands have an obvious therapeutic potential for the treatment
of HD and other polyQ-expanded disorders. A number of
approaches have been attempted previously to identify spe-
cific polyQ-binding ligands. Intrabodies developed against an
epitope of human Htt specifically bind to mHtt and reduce
its toxicity in cellular and animal models (Colby et al., 2004;1 Elsevier Ltd All rights reserved
Figure 7. PolyQ-Binding Peptoid Inhibits
mHtt Aggregates in YAC128 Mice
(A) Representative confocal images of the striatum
region of brain slices showing mHtt aggregates
(red) stained with EM48 antibody and nuclei
stained with Nissl stain (green) from ACSF-treated
(control, top) or HQP09-treated (HQP09, bottom)
YAC128 mice. ACSF (100 ml/mice) or HQP09
(2.5 mg/100 ml/mice) was delivered by ICV using
an Alzet osmotic pump for 30 days. Scale bar:
10 mm.
(B) The total mHtt aggregates area was quantified
using MetaXpress from the striatum images of
control (treated with ACSF) and HQP09-treated
mice. The mean from 15 images per mouse are
shown. The data are presented as mean ± SE
(n = 4 for YAC128 control group and n = 3 for
YAC128 HQP09 group, **p < 0.01).
(C) The total mHtt aggregates intensity was
quantified using MetaXpress from the stria-
tum images of control (treated with ACSF) and
HQP09-treated mice. The mean from 15 images
per mouse were used. The data are presented as
mean ± SE (n = 4 for YAC128 control group and
n = 3 for YAC128 HQP09 group, **p < 0.01).
See also Figures S4 and S5 and Table S2.
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Wolfgang et al., 2005). However, the therapeutic potential of
intrabodies is limited by the requirement of viral delivery. A
specific polyQ binding peptide (QBP1) was isolated in a phage
library screen (Nagai et al., 2000). When coupled with a protein
transduction domain (PTD), QBP1 suppressed polyQ-induced
neurodegeneration in cultured cells and in a Drosophila model
(Popiel et al., 2007). However, the benefit of long-term adminis-
tration of PTD-QBP1 in a mouse model of HD was limited to
weight loss phenotype (Popiel et al., 2009), whichwasmost likely
caused by low efficiency of PTD-QBP1 delivery to the brain after
intraperitoneal administration (Popiel et al., 2009). A number of
small molecules have been identified and isolated in screens
as inhibitors of polyQ aggregation. Some of these molecules
were able to reduce polyQ aggregation and toxicity in cellular
and animal models (Chopra et al., 2007; Ehrnhoefer et al.,
2006; Heiser et al., 2002; Sa´nchez et al., 2003; Wang et al.,
2005; Zhang et al., 2005). However, these molecules showed
very limited benefit in preclinical studies and none have
advanced to clinical trials so far.
Here, we took advantage of a novel peptoid technology to
identify and optimize a selective polyQ-binding ligand. Com-
pared to peptides, peptoids are more resistant to protease
degradation, more cell-permeable, more cost-effective, more
readily synthesized, and can have higher structural diversities
(Simon et al., 1992). Because of these favorable properties, pep-
toid libraries constitute rich sources of protein-binding ligands
that have in vitro and in vivo biological functions (Zuckermann
and Kodadek, 2009). Previously, peptoid technology wasChemistry & Biology 18, 1113–1125, September 23, 2011 ªused to identify specific inhibitors of
VEGF receptors (Udugamasooriya et al.,
2008a), proteosome inhibitors (Lim et al.,
2007), mimics of transcriptional activa-tion domains (Liu et al., 2005; Xiao et al., 2007), other protein-
binding ligands (Alluri et al., 2003, 2006; Simpson et al., 2009)
and to isolate diagnostically useful antibodies in a sera col-
lected from Alzheimer’s patients (Reddy et al., 2011). This tech-
nology is particularly advantageous for developing inhibitors of
protein-protein interactions, which are notoriously difficult to
target using small molecules (Hershberger et al., 2007). For
example, structure-based design was recently used to develop
a peptoid that blocked the interactions between human double
minute 2 (HDM2) protein and p53, an important target for cancer
therapeutics (Hara et al., 2006). In the present study, we used an
unbiased approach of screening a 6-mer peptoid library to
isolate a peptoid HQP09 (MW = 908) that specifically bound to
polyQ-expanded forms of mHtt and mAtx3 (Figure 2). By per-
forming structure-activity analysis, we generated a minimal
4-mer derivative HQP09_9 (MW = 585) (Figure 3). Both HQP09
and HQP09_9 prevented aggregation of mHtt in vitro (Figure 4;
Figure S3). The binding specificity and anti-aggregation activity
of HQP09 were comparable with those of QBP1 peptide (Figures
2, 4 and Figure S3). Interestingly, HQP09 and QBP1 appeared to
bind to non-overlapping sites on expanded polyQ sequence and
did not compete with each other (Figure 2). Importantly, both
HQP09 and HQP09_9 stabilized abnormal glutamate-induced
Ca2+ signals in YAC128 MSN cultures (Figure 5) and protected
YAC128 MSN from glutamate-induced apoptosis in vitro (Fig-
ure 6). HQP09_9 displayedmore potent Ca2+ stabilizing and neu-
roprotection activities than HQP09 (Figures 5 and 6), presumably
because of its smaller size and better membrane permeability.
Finally, mHtt aggregation was significantly reduced in the2011 Elsevier Ltd All rights reserved 1121
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infusion with HQP09 compared with the control group of age-
matched YAC128 mice infused with ACSF (Figure 7) without
causing significant neuronal toxicity (Figure S5). Infusion with
HQP09 also resulted in improvement of motor performance of
YAC128 mice (Figure S4).
From these studies, we concluded that HQP09 constitutes
a promising lead for developing HD therapy, especially in view
of the fact that peptoids share favorable pharmacological char-
acteristics such as resistance to degradation in vivo and good
cell membrane and blood brain barrier permeability (Zucker-
mann and Kodadek, 2009). At present, peptoid technology has
very limited application in the field of neuroscience and neurode-
generation. In a recent study, combinatorial peptoid library
was used to identify diagnostically useful antibodies in a sera
collected from Alzheimer’s patients (Reddy et al., 2011). In
another study two 3-mer peptoids were isolated as potential
neuroprotective agents in a cell-based screen for inhibitors of
glutamate-induced excitotoxicity (Montoliu et al., 2002). How-
ever, the target and the mechanism of action of those initial hits
were not identified (Montoliu et al., 2002), which made further
optimization difficult. In contrast, the target of HQP09 is known
and structure-functional optimization can be easily performed
using the competitive FP-basedbindingassay thatwedeveloped
(Figure 3). The structures of resulting peptoids can be further
optimized by taking advantage of recently solved crystal struc-
ture of Htt-17Q exon 1 fragment (Kim et al., 2009). The biological
activities of generated leads could be easily validated using the
mHtt aggregation assay (Figure 4), Ca2+ imaging/apoptosis
assays with YAC128 MSN cultures (Figures 5 and 6), and in
in vivo experiments with YAC128 mice (Figure 7). Our next goal
is to proceed in HQP09 optimization and extend this technology
to identify peptoids (and peptoids derivatives) that may be bene-
ficial to other polyQ expansion disease models, such as SCA3
and SCA2. In future studies, we plan to test this hypothesis in
experiments with SCA3-YAC84 or SCA2-58Q mouse models as
we previously described (Chen et al., 2008; Liu et al., 2009).
EXPERIMENTAL PROCEDURES
Materials and Equipment
See Supplemental Experimental Procedures online.
Animals
All animal studies and surgical procedures were approved by the University of
Texas Southwestern Medical Center Animal Care and Use Committee.
YAC128 mice (FVBN/NJ background strain) (Slow et al., 2003) were obtained
from Jackson Labs (Bar Harbor, ME). Pups were used for the preparation of
MSNs cultures at postnatal days 0–2 and maintained as previously described
(Tang et al., 2005). Adult 8–9month oldWT and YAC128micewere used to test
the efficacy of peptoids.
Generation of the Peptoid Library
The synthesis of the one-bead-one–compound peptoid library was accom-
plished using a standard combinatorial ‘‘split and pool’’ strategy in accordance
with a previously published protocol (Alluri et al., 2003), and the resulting library
consisted of 60,000 peptoids (beads). The detailed procedure of library
synthesis is described in the Supplementary Methods.
Expression, Purification, and Biotinylation of Human Htt
A first exon (EX1) fragment of the human Htt protein (The Huntington’s Disease
Collaborative ResearchGroup, 1993) (Met1-Gln66) containing 15 CAG repeats1122 Chemistry & Biology 18, 1113–1125, September 23, 2011 ª201or 82 CAG repeats was amplified by polymerase chain reaction (PCR) and
cloned into the pMAL vector with a modified 3A-linker as previously described
(Kim et al., 2009). The maltose-binding protein (MBP)-Htt-N-15Q and MBP-
Htt-N-82Q proteins were expressed in Escherichia coli BL21-RIL strain and
affinity-purified on amylose resin as previously described (Kim et al., 2009).
The MBP-Htt-N-82Q protein was labeled with biotin. For details, see Supple-
mentary Methods.
Peptoid Library Screening
The E. coli lysates were prepared as described in Supplementary Methods,
and all procedures were performed at 4C. Approximately 60,000 TentaGel
macrobeads (120 mg, manufacturer) of the synthesized peptoid library were
swollen in Tris-buffered saline (50 mM Tris, pH 7.4, 150 mM NaCl) with 0.1%
Tween 20 (TBST) for 1 hr. The beads were incubated with Binding Buffer
(10 mg/ml E. coli lysate and 0.5% BSA in TBST) for 1 hr to block non-specific
binding, and then incubated with MBP-Htt-N-82Q (200 nM) in Binding Buffer
overnight. The unbound proteins were removed by washing twice with
TBST. The washed beads were incubated with anti-MBP mouse IgG
(1:1000, New England BioLabs, Ipswich, MA) in Binding Buffer for 2 hr and
the unbound antibody was removed by several washes with TBST. The beads
were incubated with 500 ml of 5 nM Qdot 655 goat anti-mouse IgG (Invitrogen,
Eugene, OR) in Binding Buffer for 1.5 hr. Finally, after washing and removing
unbound Qdot, the beads were visualized under an Olympus IX70 fluores-
cence microscope using an excitation wavelength of 410 nm. The blue beads
with red Qdot circles were manually picked using pipette tips and pooled
together. The Qdot was stripped off the target bound to the beads and re-
probed with biotinylated bio-MBP-Htt-N-82Q protein and streptavidin-Qdot.
Hit Identification and Resynthesis of Peptoids
Each individual bead containing putative ‘‘hits’’ was heated at 90C in 30 ml of
1% SDS in H2O for 20 min, followed by three washes with phosphate-buffered
saline (PBS) and threewasheswithwater. The beadswere added to a cartridge
under stereo microscope (5x) and sequenced by Edman degradation (UT
Southwestern Medical Center Chemistry Core). The peaks for each peptoid
were compared with retention times of the 9 residues used to generate the
screening library (Figure 1B). Selected peptoids were re-synthesized on the
TentaGel beads using the same protocol used for the synthesis of the peptoid
library. For binding studies and biological assays, the peptoids were synthe-
sized on 4-methylbenzhydrylamine MBHA resin (Novabiochem, Darmstadt,
Germany), chemically cleaved off the resin, and purified by high-performance
liquid chromatography as described in Supplementary Methods.
In Vitro Binding Experiments
To prepare the (QBP1)2 beads, 15 mg of streptavidin agarose beads (Sigma, St.
Louis, MO) were saturated by 10 mg of Bio-(QBP1)2 peptide in 500 ml TBST
buffer at 4C for 1 hr. The QBP1 beads were generated using similar procedure
using Bio-QBP1 peptide. The beads were washed twice in TBST to remove
unbound peptide and used in pull-down experiments. The HQP09 and RP01
peptoids were synthesized on Tentagel Macrobeads as described for library
synthesis. Before binding experiments, 10 ml of each type of bead were
blocked with 0.5% BSA in TBST buffer at 4C for 1 hr. The MBP-Htt-N-82Q
or MBP-Htt-N-15Q fusion proteins (4 mg each) were incubated overnight
with the beads in 500 ml of 0.5%BSA (in TBST buffer). The beads were washed
twice with TBST, heated at 100C for 5 min in the gel-loading buffer, and
analyzed by SDS-PAGE and western blotting with an anti-MBP monoclonal
antibody (New England Biolabs, E8032). Full-length Atxn3–19Q and Atxn3–
77Qproteins were expressed in Sf9 cells by baculovirus infection as previously
described (Chen et al., 2008). The microsomes prepared from infected
Sf9 cells were solubilized in 1% CHAPS, dialyzed in TBST buffer for 2 hr,
and used in pull-down experiments. The precipitated samples were analyzed
by western blotting with an anti-Atxn3 monoclonal antibody (Millipore
MAB5360, Temecula, CA).
Fluorescence Polarization Assay
The fluoresceinated HQP09 peptoid was synthesized by reacting HQP09_G2
(Figure 3A) with fluorescein-5-maleimide (Thermo Scientific, #46130). The
fluoresceinated HQP09 (5 nM) was incubated with indicated concentrations
of BSA or MBP-Htt-N-82Q in the presence of 1.0 mM BSA in TBST (pH 7.4)1 Elsevier Ltd All rights reserved
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polarization values were measured using Panvera Beacon 2000 instrument
(Invitrogen). In competition experiments, HQP09 and all analogs were included
in the binding reaction in a final concentration of 300 mM.
Aggregation Assays
The filter trap and western blotting assays were performed as previously
described (Wacker et al., 2004). The aggregation of Htt53Q was initiated by
the addition of PreScission Protease (4 unites/100 mg fusion protein, Amer-
sham Biosciences/GE Healthcare, Piscataway, NJ) to purified GST-Htt53Q
protein. After cleavage, the Htt53Q proteins (6 mM) were incubated in 3%
DMSO, QBP1 peptide or peptoids (10 mM) in 20 mM Tris-HCl pH7.5,
150 mM KCl, 1 mM DTT at 37C with shaking at 800 rpm. The 2 mg aliquots
of Htt53Q were removed from the reaction, boiled in SDS-loading buffer,
and applied to a nitrocellulose membrane (0.2 mm pore size, Schleicher &
Schuell, Keene, NH) through a slot-blot manifold. After washing with SDS-
Buffer by vacuum filtering, the membranes were incubated in blocking buffer
and probed with the MW8 monoclonal antibody (gift from Paul Patterson)
raised against the last eight amino acids of Htt exon 1 (AEEPLHRP)
(Ko et al., 2001). The density of trapped Htt53Q aggregates was quantified
by using Image J (NIH, Bethesda, MD). For western blotting analysis, the
proteins and aggregates were separated by SDS-PAGE and analyzed with
the MW8 antibody.
Atomic Force Microscopy
The tapping mode AFM images were collected on an Asylum Research
MFP-3D atomic force microscope (Asylum Research, Santa Barbara, CA),
with 120-mm-long oxide-sharpened silicon nitride V-shaped NP-S cantilevers
(Veeco Instruments, Santa Barbara, CA). The samples were prepared and
incubated for 24 hr as described for aggregation assays. Immediately before
AFM experiments, the Htt53Q samples were diluted 20 times in the binding
buffer and deposited on freshly cleaved mica surface. All images were
captured in frame size of 10 3 10 mm, at a resolution of 1024 3 1024 pixels,
and with a scanning rate of 1 Hz. The driving frequency of the oscillating tip
is within the range of 810 kHz. The captured images were flattened and
plane-fitted in the second order before analysis. The number of particles
with effective diameter larger than 100 nm was counted by using Image J.
Calcium Imaging and Apoptosis Experiments
Post-natal day 1–2 pups were collected and genotyped for YAC128 by PCR.
Primary cultures of striatal MSN were established as before (Tang et al.,
2005, 2007; Wu et al., 2006). Ca2+ imaging and apoptosis experiments were
performed as we previously described (Tang et al., 2005, 2007; Wu et al.,
2006). For treatments, HQP09, HQP09_9, and RP01 peptoids were added
on DIV1 and DIV13 at a final concentration of 20 mM in both Ca2+ imaging
and apoptosis experiments. See Supplementary Methods for details.
Peptoid Delivery in Mice
The peptoid HQP09 (100 ml total volume, 25 mg/ml in ACSF) or 100 ml ACSF
was injected ICV to four groups of WT and YAC128 mice at 8–9 months old.
The peptoids were delivered by Alzet microosmotic pump 1004 (Durect
Corporation, Cupertino, CA), which was connected to a cannula via a catheter
tube from the Brain Infusion Kit 3 (Durect Corporation). After the mice were
anesthesized with a mixture of ketamine (120 mg/kg) and xylazine (16 mg/
kg, UTSW ARC), the cannula was placed into the left lateral ventricle (antero-
posterior: 0.3 mm; medium-line: 1 mm) using a Kopf (David Kopf, Tujunga,
CA) stereotaxic instrument and fixed by glass ionomer luting cement (3M
ESPE, St. Paul, MN). The Alzet pump was inserted subcutaneously in the
back of the mice and the incision was closed by absorbable polyglycolic
acid sutures.
Motor Coordination Assessments in Mice
The ‘‘beam-walk’’ test was used to assess motor coordination in mice as we
described previously (Chen et al., 2008; Liu et al., 2009; Tang et al., 2007,
2009; Wang et al., 2010) using 11-mm, round plastic beam. The ratio of the
latency for each individual mouse before and after ICV treatment was
determined.Chemistry & Biology 18, 1113–112Immunohistochemistry
After treatments, mice were anesthetized with Euthasol and perfused trans-
cardially first with 30 ml of PBS, then 50 ml of 4% paraformaldehyde (PFA)
in PBS. All mice brains were post-fixed overnight at 4C in PFA and equili-
brated in 25% (w/v) sucrose in PBS. The brains of YAC128 mice were frozen
in dry ice and sliced into 30-mm-thick coronal sections using a Leica SM
2000R sliding microtome (Bannockburn, IL). Six coronal sections that contain
the striatum (in the range from +0.86 mm to +0.14 mm relative to bregma) were
washed in PBS and blocked with mouse IgG (Vector Laboratories, Burlin-
game, CA) for 1 hr. Slices were then stained with EM48 monoclonal antibody
(MAB5374, 1:250, Millipore) which was diluted in the M.O.M. (Vector Labora-
tories) working solution with 0.25% Triton X-100 overnight. After being washed
twice in PBS, brain slices were incubated with goat anti-mouse IgG conju-
gated with AlexFluor 594 (1:500) for 2 hr and Neurotrace 500/525 for 1 hr
(1:500, Invitrogen) at RT in the dark. The slices were washed twice in PBS
and mounted on glass slides with Aqua Poly/Mount (Polysciences Inc, War-
rington, PA). Images were collected with a Zeiss spectral laser confocal micro-
scope using ZEN2009 software with excitation at 488 nm and 543 nm. The
settings for acquiring photos were: frame size: 1024 3 1024; averaging
number: 2; Z stack keeping 10 slides per view. Fifteen images per slice were
collected from the middle part of the slices (20 mm thick) to the striatum. The
confocal images were analyzed usingMetaXpress (Molecular Devices, Sunny-
vale, CA) to quantify the area containing aggregates and to determine the
intensity of mutant Htt aggregation.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
1016/j.chembiol.2011.06.010.
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